Andrew J. Cochran

Specialty / focus. Andrew (Andy) J. Cochran is a patent litigator whose practice centers on complex, high-stakes cases in life sciences — pharmaceuticals, biotechnology, and biologics/biosimilars — in federal court and before the PTAB, per his Cahill Gordon & Reindel bio. His broader docket spans enterprise software, microchip technology, and medical devices, and he has an extensive patent-prosecution background (automotive hybrid systems, medical devices, oncology). His tracked matters are dominated by the SportsCastr Inc. (d/b/a PANDA Interactive) campaign involving live sports-streaming video/data architecture patents, with supporting work in Hatch-Waxman and BPCIA litigation (Galderma's Oracea®, a Humira® biosimilar dispute, Entereg, and an extended-release ulcerative colitis product).

Side preference. He works both sides — tracked appearances split 2 plaintiff-side / 2 defendant-side, all as lead counsel. In the SportsCastr matters he has defended the patent owner against IPR petitions filed by Genius Sports Ltd. and Sportradar AG, while the parallel E.D. Tex. litigation (SportsCastr Inc. v. Sportradar Group AG, No. 2:23-cv-00472-JRG, consolidated with the Genius action and adding antitrust claims) shows him on the patent-owner/plaintiff side. His bio also reflects a mix of patent-owner representation (an individual inventor in a microchip case; a patent owner defending an IPR on a long-acting addiction-treatment product) and accused-infringer/defense work for pharmaceutical companies.

Firm context & notable outcomes. Cochran is a partner at Cahill Gordon & Reindel in New York (elected to partnership effective January 1, 2025; joined as counsel in February 2023). Previously he was a senior associate at King & Spalding (2018–2023), an associate at Paul Hastings, and an associate at Pearl Cohen, where his practice was prosecution-heavy; several of his bio's matters predate Cahill. Notable tracked outcomes: as lead counsel for patent owner SportsCastr in IPR2024-01305, -01307 through -01311 (Genius Sports), he argued the December 2025 oral hearing, but the Board issued final written decisions in March 2026 finding the challenged claims unpatentable — an adverse result. In the parallel Sportradar IPRs (IPR2025-00265/266/268/269/273/275), he secured a Director-level discretionary denial of institution (June 2025), preserving those patents.

PTAB / IPR experience. Substantial and recurring: lead counsel in roughly a dozen IPR proceedings in the SportsCastr campaign, plus a patent-owner IPR defense at his prior firm, spanning Board trials, FWD-stage advocacy, and Director discretionary-denial practice. He has also spoken at ACI's Paragraph IV Disputes Conference on § 112 issues post-Amgen v. Sanofi.

Bar / education. New York (2014); USPTO Reg. No. 69,620; admitted to the Federal Circuit and E.D. Tex. J.D., Fordham University School of Law (2013); M.S. (2008) and B.S. (2006), The Ohio State University.